Angtai Weijing Medical Technology (Shanghai) Co., Ltd., a Chinese developer of high-precision microsurgical robotic systems, has completed a Series B financing round worth several hundred million RMB. The round was jointly backed by leading industrial investors and top-tier venture capital firms, with Chunmu Capital serving as the exclusive financial advisor.

The new capital will be used to enhance the company’s core technological capabilities, expand its microsurgical robotics product ecosystem, accelerate clinical and regulatory progress, and advance its global market strategy.

Angtai Weijing’s core portfolio includes three surgical robotic systems:

• Universal Microsurgical Robot – designed for multi-specialty use across ENT, neurosurgery, vascular, and reconstructive procedures, enabling ultra-precise operations that complement existing robotic systems.

• Ophthalmic Surgical Robot – now in the final stage of registration for market approval after completing clinical trials, this system filters out hand tremors and enables sub-millimeter precision for delicate retinal surgeries.

• Endo-Gastrointestinal Robotic Platform – currently under development and preclinical validation.

This funding round marks a significant step forward in Angtai Weijing’s efforts to lead innovation in ophthalmic and microsurgical robotics, reinforcing China’s growing presence in the global high-precision medical robotics field.

Sep 29, 2025, MedChina